Search clinical trials for: Nituzumab/placebo

Total 53923 results

Gilead Sciences

Completed

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Myelofibrosis

United States
Sun Yat-sen University
Zhejiang Cancer Hospital; Guangxi Medical University; Wuhan University; Fujian... and other collaborators

Completed

Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma

Stage IV Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Nicola Goekbuget

Recruiting

Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL

Precursor Cell Lymphoblastic Leukemia

Germany
Anhui Provincial Hospital

Recruiting

Neoadjuvant Chemoradiotherapy Combined With Camrelizumab and Nimotuzumab for Esophageal Squamous Cell Carcinoma

Toxicity, Drug

China
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)

Lymphoma, B-Cell
Fudan University

Completed

Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Cancer

China
Medical College of Wisconsin

Active, not recruiting

Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia (ALL2418)

Acute Lymphoid Leukemia

Italy
Fudan University

Completed

Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Nasopharyngeal Carcinoma

China
Pfizer

Completed

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

United States, Spain, France, Switzerland, United Kingdom, Belgium, Germany
Guiyang Medical University

Unknown

By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC

Nasopharyngeal Carcinoma

China
SFJ Pharmaceuticals X, LTD.
Merck KGaA, Darmstadt, Germany; AIO-Studien-gGmbH; Academic and Community Cancer... and other collaborators

Withdrawn

Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer. (AMELION)

Metastatic Colorectal Cancer
Air Force Military Medical University, China

Unknown

Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer

Cervical Cancer

China
Biotech Pharmaceutical Co., Ltd.

Recruiting

Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children

Diffuse Intrinsic Pontine Glioma

China
Pfizer

Completed

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

Leukemia | Precursor b-Cell Lymphoblastic Leukemia-Lymphoma | ACUTE LYMPHOBLASTIC LEUKEMIA

United States, Spain, Taiwan, Singapore, India, Hungary, Turkey, Poland
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma (NOTABLE-307)

Gastric or Esophagogastric Junction Adenocarcinoma
Gilead Sciences

Completed

A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer

United States, Russian Federation
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy

Acute Lymphocytic Leukemia
Chinese PLA General Hospital

Unknown

Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer

Unresectable Pancreatic Cancer

China
Gilead Sciences

Completed

Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis

Liver Fibrosis

United States
Joseph Jurcic

Withdrawn

Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia
Zhejiang University

Withdrawn

Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma

Stage IV Esophageal Squamous Cell Carcinoma

China
Peking University
Chinese PLA General Hospital

Unknown

Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma (NIEGA)

Stomach Neoplasms

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Acute Lymphoid Leukemia

China
Versailles Hospital

Active, not recruiting

Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL (EWALL-INO)

Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP)

France
Fudan University
The First Affiliated Hospital of Xiamen University; Fujian Province Tumor Hospital

Completed

Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC

Nasopharyngeal Carcinoma

China
Merck KGaA, Darmstadt, Germany

Completed

Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer

Gastric Cancer | Esophageal Cancer

United Kingdom
Pfizer

Active, not recruiting

Besponsa Post Marketing Surveillance Study

Hematologic Maligmancy

Korea, Republic of
Biotech Pharmaceutical Co., Ltd.

Terminated

Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer

China
YM BioSciences

Terminated

Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer

Colorectal Cancer

Canada
Tianjin Medical University Second Hospital

Recruiting

Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

Solid Tumor | EGFR Amplification

China
Peking University

Unknown

Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer

Esophageal Squamous Cell Cancer

China
Air Force Military Medical University, China

Recruiting

GNT Induction Treatment in Locally Advanced NPC

Nasopharyngeal Carcinoma

China
YM BioSciences

Completed

Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma

Recurrent Diffuse Pontine Gliomas

United States, Canada, Israel
Fudan University

Not yet recruiting

Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms

Pancreatic Neuroendocrine Neoplasm

China
Eye & ENT Hospital of Fudan University

Not yet recruiting

Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery

Head and Neck Squamous Cell Carcinoma

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive

Minimal Residual Disease | Bone Marrow Transplant | Ph+ ALL

China
Pfizer

Active, not recruiting

A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Seagen Inc.

Completed

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

Acute Myeloid Leukemia

United States
Cancer Institute and Hospital, Chinese Academy...

Completed

Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical Trial

Esophageal Cancer

China
Biotech Pharmaceutical Co., Ltd.

Completed

Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer

Advanced Esophageal

China
Yonsei University

Completed

Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer (DATE)

Non Small Cell Lung Cancer (NSCLC)

Korea, Republic of
Biotech Pharmaceutical Co., Ltd.

Completed

Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer

Esophageal

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaborators

Recruiting

Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Nasopharyngeal Diseases | Head and Neck Neoplasm

China
Fujian Cancer Hospital
Zhejiang Cancer Hospital; Sun Yat-sen University; Jiangxi Provincial Cancer Hospital and other collaborators

Unknown

Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

China
Alison Walker
Seagen Inc.

Terminated

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

B-Cell Lymphoma

United States, Belgium, Korea, Republic of, Switzerland, France, Poland, Spain, Hong Kong, Australia, Germany, Italy, Netherlands, United Kingdom
Ruijin Hospital

Completed

A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Resectable Pancreatic Cancer
Gilead Sciences
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis

Hepatitis C | HIV | Liver Fibrosis | HIV/HCV Co-infection

United States

Search clinical trials for: Nituzumab/placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations